Commercial partner, Zambon, has announced a sublicence agreement with US WorldMeds for the US commercialisation of Parkinson’s disease (PD) therapy Xadago (safinamide). Under the agreement’s terms Zambon will give Newron a share of undisclosed, upfront milestone and royalty payments made by US WorldMeds, in addition to a milestone payment on FDA approval (we estimate €9m, not included in our forecasts). Importantly Xadago’s US PDUFA date is looming (29 March 2016) and a
18 Mar 2016
US partner on board ahead of PDUFA date
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
US partner on board ahead of PDUFA date
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
18 Mar 2016 -
Author:
Dr Susie Jana -
Pages:
2
Commercial partner, Zambon, has announced a sublicence agreement with US WorldMeds for the US commercialisation of Parkinson’s disease (PD) therapy Xadago (safinamide). Under the agreement’s terms Zambon will give Newron a share of undisclosed, upfront milestone and royalty payments made by US WorldMeds, in addition to a milestone payment on FDA approval (we estimate €9m, not included in our forecasts). Importantly Xadago’s US PDUFA date is looming (29 March 2016) and a